Energy drinks and stimulant supplements appear far more often in federal safety reports involving cardiac arrest and heart attacks than other foods and supplements do, according to research released by the American Heart Association on Monday. The analysis, led by researchers at the University of Virginia School of Medicine, reviewed 28,345 adverse-event reports submitted to the US Food and Drug Administration between 2017 and 2025, covering people aged 13 and older.
Cardiac arrest was reported about 11 times more often in connection with products containing caffeine or other stimulants than with products without them, the American Heart Association said. Reports involving the stimulant products were also about 4.5 times more likely to mention heart attacks and roughly four times more likely to mention heart palpitations or ventricular arrhythmia, a dangerous rhythm disturbance in the heart's lower chambers. Only 854 of the reports involved stimulant products.
The age pattern drew particular attention from the researchers. Adults aged 18 to 34 accounted for about 45 percent of the reports linking these products to cardiovascular events, HealthDay reported, even though that age group is not usually considered at high risk for heart emergencies. Lead author Sai Samayamanthula, a fourth-year medical student at the University of Virginia, noted that the products are marketed as everyday pick-me-ups and sold beside soda and bottled water.
The stimulant ingredients in the reports extended well beyond caffeine alone, according to the American Heart Association. They included plant extracts such as guarana, yerba mate and green tea or coffee extracts, along with substances such as synephrine, yohimbine and DMAA. Unlike medicines, energy drinks and dietary supplements are regulated as foods, so they do not pass through the premarket safety testing that drugs must complete before reaching store shelves.
The researchers and outside experts were careful to stress the limits of the findings. The work is a preliminary conference abstract that has not yet been peer-reviewed, and because the FDA database relies on voluntary reports, it shows an association rather than proving the products caused the events, HealthDay reported. The study will be presented at the association's Scientific Sessions 2026 in Chicago from November 6 to 9.
Sources: American Heart Association, HealthDay